Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Diagnosis and treatment of vasculitic neuropathy

Steven David Brass, MD, MPH, MBA
Simon M Helfgott, MD
Section Editors
Peter A Merkel, MD, MPH
Jeremy M Shefner, MD, PhD
Deputy Editor
Monica Ramirez Curtis, MD, MPH


Vasculitic diseases can affect any organ or tissue, including the peripheral nerves. When vasculitis affects the vasa nervorum, the results are often critical ischemia to peripheral nerves and potentially profound clinical sequelae.

Vasculitic neuropathy is usually only one feature of a systemic condition that can involve the skin, lungs, kidneys, and other organs. As an example, the group of vasculitic disorders commonly associated with antineutrophil cytoplasmic antibodies (ANCA) (ie, granulomatosis with polyangiitis [Wegener's], microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis [Churg-Strauss]) often cause vasculitic neuropathy. Polyarteritis nodosa (PAN) and mixed cryoglobulinemia are also prone to involve the peripheral nervous system.

In a minority of patients with vasculitic neuropathy, the peripheral nervous system vasculitis occurs in isolation. In this setting, the disorder is referred to as nonsystemic vasculitic neuropathy or isolated peripheral nervous system vasculitis [1-4].

Even in the absence of frank systemic vasculitis, nonsystemic vasculitic neuropathy can be a devastating illness, leading to severe functional disabilities from which some patients never recover fully. Because the regeneration of peripheral nerves may require months or years, the goals of therapy are to control the inflammation within the vasa nervorum as quickly as possible to prevent or minimize nerve damage.

This topic will review the diagnosis and treatment of vasculitic peripheral neuropathy. The clinical manifestations of vasculitic neuropathy are presented separately. (See "Clinical manifestations of vasculitic neuropathy".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 03, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain 1987; 110 ( Pt 4):843.
  2. Collins MP, Periquet MI. Non-systemic vasculitic neuropathy. Curr Opin Neurol 2004; 17:587.
  3. Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain 1996; 119 ( Pt 5):1441.
  4. Mathew L, Talbot K, Love S, et al. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM 2007; 100:41.
  5. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21:883.
  6. Moore PM. Vasculitis: diagnosis and therapy. Semin Neurol 1994; 14:159.
  7. Olney RK. AAEM minimonograph #38: neuropathies in connective tissue disease. Muscle Nerve 1992; 15:531.
  8. Collins MP, Periquet MI, Mendell JR, et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003; 61:623.
  9. Collins MP, Mendell JR, Periquet MI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000; 55:636.
  10. Vrancken AF, Hughes RA, Said G, et al. Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev 2007; :CD006050.
  11. Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis 2015; 7:45.
  12. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843.
  13. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.
  14. Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol 2017; 13:302.